Initial skin necrosis presentation at emergency room was associated with fulminant clinical course and mortality in patients with Vibrio necrotizing fasciitis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 10 2023
27 10 2023
Historique:
received:
20
03
2023
accepted:
25
10
2023
medline:
30
10
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Necrotizing fasciitis (NF) is a life-threatening infection. Skin necrosis is an important skin sign of NF. The purposes of this study was to investigate the initial skin conditions of Vibrio NF patients between emergency room (ER) to preoperative status, to compare the clinical and laboratory risk indicators of the skin necrosis group and non-skin necrosis group when they arrived at ER, and to evaluate whether initial cutaneous necrosis related to fulminant course and higher fatalities. From 2015 to 2019, seventy-two Vibrio NF patients with surgical confirmation were enrolled. We identified 25 patients for inclusion in the skin necrosis group and 47 patients for inclusion in the non-skin necrosis group due to the appearance of skin lesion at ER. Seven patients died, resulting in a mortality rate of 9.7%. Six patients of skin necrosis group and one patient of non-skin necrosis group died, which revealed the skin necrosis group had a significantly higher mortality rate than the non-skin necrosis group. All the patients in the skin necrosis group and 30 patients of non-skin necrosis group developed serous or hemorrhagic bullous lesions before operation (p = 0.0003). The skin necrosis group had a significantly higher incidence of APACHE score, postoperative intubation, Intensive care unit stay, septic shock, leukopenia, higher counts of banded leukocytes, elevated C-reactive protein (CRP), and lower serum albumin level. Vibrio NF patients presenting skin necrosis at ER were significantly associated with fulminant clinical courses and higher mortality. Physicians should alert the appearance of skin necrosis at ER to early suspect NF and treat aggressively by those clinical and laboratory risk indicators, such as elevated APACHE score, shock, leukopenia, higher banded leukocytes, elevated CRP, and hypoalbuminia.
Identifiants
pubmed: 37891231
doi: 10.1038/s41598-023-45854-1
pii: 10.1038/s41598-023-45854-1
pmc: PMC10611701
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18410Informations de copyright
© 2023. The Author(s).
Références
Int J Infect Dis. 2012 Mar;16(3):e159-65
pubmed: 22154593
BMC Infect Dis. 2021 Aug 9;21(1):771
pubmed: 34372768
Int J Gen Med. 2015 May 14;8:195-202
pubmed: 25999758
Antibiotics (Basel). 2022 Oct 22;11(11):
pubmed: 36358109
Microbiol Immunol. 2017 Jan;61(1):1-11
pubmed: 28111826
J Orthop Surg Res. 2019 Mar 6;14(1):73
pubmed: 30841912
Infection. 2021 Feb;49(1):135-144
pubmed: 33389697
BMC Infect Dis. 2020 Jan 20;20(1):60
pubmed: 31959118
World J Emerg Surg. 2022 May 27;17(1):28
pubmed: 35624468
Front Surg. 2014 Sep 29;1:36
pubmed: 25593960
Curr Opin Infect Dis. 2005 Apr;18(2):101-6
pubmed: 15735411
J Bone Joint Surg Am. 2003 Aug;85(8):1454-60
pubmed: 12925624
Cureus. 2021 Sep 7;13(9):e17806
pubmed: 34660016
World J Emerg Surg. 2018 Oct 1;13:45
pubmed: 30302124
Clin Infect Dis. 2003 Jul 15;37(2):272-80
pubmed: 12856219
Surg Infect (Larchmt). 2022 Apr;23(3):288-297
pubmed: 35180367
J Emerg Trauma Shock. 2017 Oct-Dec;10(4):205-210
pubmed: 29097860
J Hosp Infect. 2010 Aug;75(4):249-57
pubmed: 20542593
Clin Orthop Relat Res. 2010 Aug;468(8):2230-7
pubmed: 20232179
J Am Acad Orthop Surg. 2000 May-Jun;8(3):151-8
pubmed: 10874222
Am J Emerg Med. 2008 Mar;26(3):316-9
pubmed: 18358943
Intern Med. 2010;49(12):1051-7
pubmed: 20558917
J Appl Microbiol. 2005;98(5):1011-9
pubmed: 15836469
PLoS One. 2015 Jul 21;10(7):e0132775
pubmed: 26196941
Am J Surg. 2000 May;179(5):361-6
pubmed: 10930480
Int J Infect Dis. 2023 Mar;128:41-50
pubmed: 36521588
Am J Emerg Med. 2008 Feb;26(2):170-5
pubmed: 18272096
Int J Dermatol. 2007 Oct;46(10):1036-41
pubmed: 17910710
Pharmaceutics. 2020 Aug 05;12(8):
pubmed: 32764269